A new background subtraction method for Western blot densitometry band quantification through image analysis software G Gallo-Oller, R Ordonez, J Dotor Journal of immunological methods 457, 1-5, 2018 | 182 | 2018 |
Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma ØH Hald, L Olsen, G Gallo-Oller, LHM Elfman, C Løkke, P Kogner, ... Oncogene 38 (15), 2800-2813, 2019 | 64 | 2019 |
miRNA-7 and miRNA-324-5p regulate alpha9-Integrin expression and exert anti-oncogenic effects in rhabdomyosarcoma C Molist, N Navarro, I Giralt, P Zarzosa, G Gallo-Oller, G Pons, ... Cancer Letters 477, 49-59, 2020 | 30 | 2020 |
Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluation E Sandén, C Dyberg, C Krona, G Gallo-Oller, TK Olsen, J Enríquez Pérez, ... Scientific Reports 7 (1), 46366, 2017 | 29 | 2017 |
P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines G Gallo-Oller, A Vollmann-Zwerenz, B Meléndez, JA Rey, P Hau, J Dotor, ... Cancer letters 381 (1), 67-75, 2016 | 29 | 2016 |
Dickkopf proteins and their role in cancer: a family of Wnt antagonists with a dual role I Giralt, G Gallo-Oller, N Navarro, P Zarzosa, G Pons, A Magdaleno, ... Pharmaceuticals 14 (8), 810, 2021 | 21 | 2021 |
RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism A Azatyan, G Gallo-Oller, Y Diao, G Selivanova, JI Johnsen, ... Cancer letters 442, 341-350, 2019 | 16 | 2019 |
Transforming growth factor beta (TGF-β) activity in immuno-oncology studies G Gallo-Oller, M Di Scala, F Aranda, J Dotor Methods in Enzymology 636, 129-172, 2020 | 11 | 2020 |
Quantitative method for in vitro matrigel invasiveness measurement through image analysis software G Gallo-Oller, JA Rey, J Dotor, JS Castresana Molecular biology reports 41, 6335-6341, 2014 | 10 | 2014 |
Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma N Navarro, C Molist, J Sansa-Girona, P Zarzosa, G Gallo-Oller, G Pons, ... Cellular and Molecular Life Sciences 79 (11), 546, 2022 | 9 | 2022 |
Dickkopf-1 inhibition reactivates Wnt/β-catenin signaling in rhabdomyosarcoma, induces myogenic markers in vitro and impairs tumor cell survival in vivo I Giralt, G Gallo-Oller, N Navarro, P Zarzosa, G Pons, A Magdaleno, ... International Journal of Molecular Sciences 22 (23), 12921, 2021 | 9 | 2021 |
PPM1D Is a Therapeutic Target in Childhood Neural Tumors J Milosevic, D Treis, S Fransson, G Gallo-Oller, B Sveinbjörnsson, ... Cancers 13 (23), 6042, 2021 | 8 | 2021 |
Genome-wide microarray expression and genomic alterations by array-CGH analysis in neuroblastoma stem-like cells R Ordóñez, G Gallo-Oller, S Martínez-Soto, S Legarra, N Pata-Merci, ... PloS one 9 (11), e113105, 2014 | 8 | 2014 |
High Expression of PPM1D Induces Tumors Phenotypically Similar to TP53 Loss-of-Function Mutations in Mice J Milosevic, S Fransson, M Gulyas, TK Olsen, G Gallo-Oller, D Treis, ... Cancers 13 (21), 5493, 2021 | 7 | 2021 |
Sonic hedgehog inhibition reduces in vitro tumorigenesis and alters expression of Gli1-target genes in a desmoplastic medulloblastoma cell line R García-López, B Vera-Cano, A Vacas, FJ Rosa-Fernández-Pacheco, ... | 7 | 2013 |
Targeting the hedgehog pathway in rhabdomyosarcoma P Zarzosa, L Garcia-Gilabert, R Hladun, G Guillén, G Gallo-Oller, G Pons, ... Cancers 15 (3), 727, 2023 | 6 | 2023 |
In vitro tumorigenicity and stemness characterization of the U87MG glioblastoma cell line based on the CD133 cancer stem cell marker A Vacas-Oleas, J de la Rosa, R García-López, B Vera-Cano, ... Open Access Sci Rep 2, 609, 2013 | 5 | 2013 |
TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma G Gallo-Oller, G Pons, J Sansa-Girona, N Navarro, P Zarzosa, ... Experimental Hematology & Oncology 13 (1), 38, 2024 | 3 | 2024 |
Analysis of cancer genomic amplifications identifies druggable collateral dependencies within the amplicon G Pons, G Gallo-Oller, N Navarro, P Zarzosa, J Sansa-Girona, ... Cancers 15 (6), 1636, 2023 | 2 | 2023 |
Combined inhibition of MDM2 and PARP lead to a synergistic anti-tumoral response in p53 wild-type rhabdomyosarcoma G Pons, G Gallo-Oller, L García-Gilabert, P Zarzosa, J Sansa-Girona, ... Cancer Research 84 (6_Supplement), 5473-5473, 2024 | 1 | 2024 |